SlideShare una empresa de Scribd logo
1 de 49
Latest Research on Metastatic Breast
Cancer from San Antonio Breast
Cancer Symposium 2015 and beyond
Tiffany A.Traina, MD
Section Head,Triple Negative Breast Cancer Clinical Research Program
Associate Member, Breast Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine, Weill Cornell Medicine
Topics of interest from SABCS 2015
• Neoadjuvant carboplatin
• IMMU-132
TNBC
• TH3RESA trialHER2+
• JAVELIN
• KEYNOTE
Immunotherapy
• ABCSG18
• CREATE-X
Other
Neoadjuvant platinum for
TNBC?
Why platinums inTNBC?
• Platinum activity in BRCA-
associated BC
– BRCA1 is a key mediator of DNA
damage response
– BRCA deficient cells have impaired
ability to repair damage
• 80% of BRCA1-associated BC areTN
• “BRCAness” ofTNBC
– SporadicTNBC have genomic
instability similar to BRCA1-associated
breast cancer
• High pCR rates inTNBC pilot trials
Wilson C A , et al Nat Genet 1999;21:236
GeparSixto:
Does carboplatin increase response?
von Minckwitz et al Lancet Oncology 2014 Jun; 15(7)
N = 315
Yes, Carboplatin increases pCR
pCR (ypT0N0)
von Minckwitz et al Lancet Oncology 2014 Jun; 15(7)
CALGB 40603: Does carboplatin increase pCR?
Sikov et al, J Clin Oncol 2015 Jan 1;33(1):13-21
Paclitaxel 80 mg/m2 wkly x 12 ddAC x 4
Bevacizumab 10 mg/kg q2wks x 9
Bevacizumab 10 mg/kg q2wks x 9
CarboplatinAUC 6 q3wks x 4
CarboplatinAUC 6 q3wks x 4
Paclitaxel 80mg/m2 weekly x 12
Surgery
XRT
No Adjuvant
Systemic
Treatment
Planned
Paclitaxel 80 mg/m2 wkly x 12
Paclitaxel 80 mg/m2 wkly x 12
Paclitaxel 80 mg/m2 wkly x 12
ddAC x 4
ddAC x 4
ddAC x 4
N = 443
2 X 2
Randomization
Primary Endpoint: pCR Breast (ypT0/is N any)
Key
Eligibility
St II-III
ER/PR
<10%
HER2 (-)
N=212
Yes, Carboplatin increases pCR
46% (40-53%) 60% (54-66%)
Odds Ratio: 1.76
p = 0.0018
41% (35-48%) 54% (48-61%)
Odds ratio: 1.71
p = 0.0029
PaclitaxelddAC
Significant side effects limit tolerability
Slide courtesy of Bill Sikov; SABCS 2013
Von Minckwitz et al S2-04 SABCS 2015
Geparsixto: DFS improved with addition of
carboplatin
3 yr DFS:
76.1% vs.
85.8%
HR 0.59
P=0.03
Sikov et al S2-05 SABCS 2015
CALGB: Carboplatin did NOT improve breast
cancer related survival
CALGB: Carboplatin did NOT improve OS using a
conventional anthracycline, cyclophosphamide and
taxane containing regimen
Sikov et al S2-05 SABCS 2015
Why the discrepancy?
Challenge of pCR as a surrogate endpoint
Berry D and HudisC, JAMAOncology, July 2015
• Trials were not powered to show
survival advantage
• Statistically, need a very large
pCR difference to see a survival
advantage
Many unanswered questions re: the
role of platinum inTNBC
• Does the backbone regimen
matter?
• Does type of platinum matter?
For individual trials, no association between pCR
and survival benefit
Cortazar et al, Lancet July 2014
Is neoadjuvant platinum a new standard?
No, data fell short and uncertainty remains
• Await molecular/biomarker correlatives to narrowly select who
may benefit
– BRCA status
– Other markers of DNA repair problems (HRD)
• Carboplatin added to anthracycline/taxane reasonable when
the goal of pre-op therapy is to reduce tumor volume
• Would not routinely recommend platinum in the adjuvant
setting forTNBC based on these data
IMMU-132
Sacituzumab Govitecan (IMMU-132)
A next-generation irinotecan of interest inTNBC
• Trop-2 expressed in >90% ofTNBC
• IMMU-132 is a antibody-drug
conjugate of humanized anti-Trop-
2 coupled with SN-38, the active
metabolite of irinotecan
• Phase I/II ongoing
– N = 60 patients withTNBC
– ≥2 prior chemotherapy regimens;
median of 5 priors
– ORR = 31% (18/58);CBR24 = 45%
– Median PFS 6 months (95% CI: 4.1-
9.4mo)
– Most common side effects: low white
cells, diarrhea, fatigue, anemia
– Serious diarrhea 3% (relatively rare)
Bardia et al, Abstract #1016; ASCO 2015; SABCS 2015
FDA Assigns Sacituzumab Govitecan
Breakthrough Designation forTNBC!
February 8, 2016
"We believe breakthrough therapy designation for IMMU-
132 further validates this potential therapeutic for
patients withTNBC, and we are delighted to receive this
important recognition."
Cynthia L. Sullivan
President and CEO of Immunomedics
“The planned phase III trial of sacituzumab govitecan, on which Immunomedics is working
with the FDA, is a multicenter, international, randomized, open-label study that aims to accrue
328 patients with relapsed/refractory metastaticTNBC following ≥2 prior chemotherapies,
including a taxane.The primary outcome measure will be PFS, with secondary endpoints
includingOS,ORR, duration of response, and time to onset of response.”
HER2+ Breast Cancer
Hudis C. N Engl J Med 2007;357:39-51; Slamon et al NEJM 2001;
Targeting HER2 improves breast cancer
survival!
T-DM1
Average number DM1 molecules/monoclonal antibody=3.5
1. Beeram M., et al. J Clin Oncol. 2008;
26 (May 20 suppl; abstr 1028).
TDM1 vs.TPC in HER2+ MBC
Wildiers et al; SABCS 2015
TDM1 improves OS in HER2+ MBC
Wildiers et al; SABCS 2015
Immunotherapy
Immunotherapy rationale
• Normal part of
immune
regulation
• Antibodies
that block the
PD-1 pathway
can reactivate
T-cell activity
and
proliferation
• Leading to
enhanced
antitumour
immunity
Wolchok & Chan
Nature 2014
Pembrolizumab
Nivolumab
Atezolizumab
Immunotherapy forTNBC
TNBCs have high PD-L1
Early but encouraging results
Pembrolizumab (SABCS 2014)
• PD1 inhibitor. Blocks ability
of tumor to deactivate
immune system
• Small Phase 1 trial
• Responses in ~20% of
women with PD-L1+TNBC
• Well tolerated
Atezolizumab = MPDL3280A
(AACR 2015)
• PD-1 inhibitor
• Small Phase 1 trial
• Responses in ~20% of
patients
• Well tolerated
Many potential immunotherapy trials!
Pembrolizumab
1. Pembrolizumab +
capecitabine or paclitaxel
(PI Heather McArthur)
2. Pembrolizumab + eribulin
(industry)
3. Carboplatin +/- pembro
(TBCRC: PI Hope Rugo)
4. Pembro vs.TPC (Industry)
Atezolizumab (MPDL3280A )
• Carboplatin +/-
atezolizumab (TBCRC:
Vanderbilt)
• Nab-paclitaxel +/-
atezolizumab (Industry)
JAVELIN: Ph 1b of Avelumab in SolidTumors
Trial Design
• Fully humanized anti-PD1
antibody
• Expansion cohort MBC
– </= 3 lines of cytotoxic tx
– PriorT + A
– Unselected for PD-L1
expression or molecular
subtype
Patient Characteristics
• TNBC 35%
• ER+ 43%
• HER2+ 15%
• Median 3 regimens (0-10)
Dirix et al; SABCS 2015
JAVELIN:Toxicity
Dirix et al; SABCS 2015
Activity of avelumab in pts with MBC
Dirix et al; SABCS 2015
KEYNOTE: Pembrolizumab in PD-L1+ ER+ MBC
Pembrolizumab
• Anti-PD-L1 antibody
• Activity in PD-L1+TNBC
– ORR 19% (5/27; Nanda
SABCS 2014)
– 3/5 responders on drug >11m
• PD-L1 expression inversely
correlated with ER
expression
KEYNOTE-028
• Phase 1b multicohort trial
– ER+ HER2- MBC
– Failure of or inability to receive
standard therapy
– PD-L1+ (≥1% tumor or stroma)
– Measurable disease
• Pembrolizumab 10mg/kg q2
weeks until 8 week scan
– Confirmed POD after 4 weeks
– CR/PR/SD to 24mo or POD or
tox
Rugo et al; SABCS 2015
KEYNOTE-028
Pt Characteristics
• 19% (48) of 261 screened
were PD-L1+
• N=25 on study
– 44% had ≥5 prior lines
Rugo et al; SABCS 2015
ABCSG-18: A role for
“adjuvant” denosumab
ABCSG18: Background
• Adjuvant bisphosphonates have been associated with a significantly
reduced rate of breast cancer recurrence in bone and improved survival in
postmenopausal women with breast cancer[1]
• ABCSG18 trial: phase III trial of denosumab vs placebo in AI-treated
postmenopausal women with early HR+ breast cancer
– Primary analysis: significant reduction in fracture risk with denosumab vs
placebo[2]
• HR: 0.50 (95% CI: 0.39-0.65; P < .0001)
– IDMC recommended unblinding following results of primary analysis, with DFS
analysis to be completed before unblinding
• SABCS report from the ABCSG18 study includes the impact of
denosumab on DFS in postmenopausal pts with early HR+ breast cancer
on AIs[3]
1. EBCTCG, et al. Lancet. 2015;386:1353-1361.
2. Gnant M, et al. Lancet. 2015;386:433-443.
3. Gnant M, et al. SABCS 2015. Abstract S2-02.
ABCSG-18: Study Design
• Prospective, randomized, double-blind, placebo-controlled phase III trial
• Primary endpoint: time to first clinical fracture
• Secondary endpoints: % change in BMD, vertebral fractures, DFS, OS,
BoneM+FS, safety
Postmenopausal pts
with early HR+ breast
cancer receiving
adjuvant AI therapy*
(N = 3425)
Denosumab 60 mg SC Q6M
(n = 1711)
Placebo SC Q6M
(n = 1709)
Gnant M, et al. Lancet. 2015;386:433-443.
*Pts excluded if history of IV bisphosphonate, SERMS,Cushing’s disease, Paget’s disease, hypercalcemia,
hypocalcemia, hyperprolactinemia, or other active metabolic bone disease.
ABCSG-18: Disease-Free Survival
• ITT analysis consistent with sensitivity analysis in which pts switching to another bone-active treatment
were censored
– Hazard ratio, denosumab vs placebo: 0.807 (95% CI: 0.66-0.99; P = .0424)
Gnant M, et al. SABCS 2015. Abstract S2-02.
Impact of Denosumab vs Placebo on DFS (ITT)
100
90
80
70
60
0
Disease-FreeSurvival(%)
Mos Since Randomization
900 6 12 18 24 30 36 42 48 54 60 66 72 78 84
93.8%
88.9%
83.5%
92.6%
86.8%
80.4%
.0510Placebo
Denosumab
Number of
Events/Patients
HR (95% CI)
vs Placebo P value
203/1709
167/1711
0.816 (0.66-1.00)
Denosumab improves DFS when consider cross-over
Gnant et al; SABCS 2015
Indirect Comparison with EBCTCG, Lancet 2015
Denosumab data is consistent with EBCTG
3% absolute reduction in breast cancer mortality in
post-menopausal women (18%)
CREATE-X: Ph III trial of
adjuvant capecitabine
Does capecitabine improve DFS after pre-op
chemo?
Lee S-J,Toi et al; SABCS 2015
Capecitabine 2,500 mg/m2/day po Day 1-14 in a 21-day cycle x6 cycles
** Safety interim analysis after N=50, IDMC recommended 8 cycles of tx
CREATE-XTrial Design
Statistics
• Primary endpoint 5y DFS
– Estimate 62% vs 70%
– HR 0.74, 2 sided alpha 5%
– 352 events expected from
900 pts
– Planned 1 interim analysis for
DFS at 2 years
Eligibility
• Age 20-74
• Stage I-IIIB
• HER2 negative
• Non-pCR and/or LN+ after
pre-operative
chemotherapy
• No prior oral 5-FU
Lee S-J,Toi et al; SABCS 2015
CREATE-X Results
Patient characteristics
• Med age 48y
• ~60% Premenopausal
• ~40% Stage III
• ~60% LN+
• ~63% ER+
• NeoadjTx Received
– A+T/AT 94%
– TC 1%
– 5-FU containing 60%
• Endocrine tx (67%) and
radiation (72%)
Capecitabine Compliance
• Reduced: 24-37%
• Discontinued: ~18-25%
≥Gr 3Tox Control Capecitabine
Neutropenia 1.6% 6.6%
Diarrhea 0.4% 3%
HFS 10.9%
Lee S-J,Toi et al; SABCS 2015
Capecitabine improves DFS/OS following pre-
operative chemotherapy
Lee S-J,Toi et al; SABCS 2015
5% improvement in overall survival!
Across all subsets
42% improvement ifTNBC
Exciting innovation and
technology…
Cutting edge technology to personalize cancer
treatment!
Clinical trial enrolling now at MSK…
Device Drugs
Lead PI:Traina. NCT# 02521363
ThankYou!

Más contenido relacionado

La actualidad más candente

Hormonal treatment of breast cancer
Hormonal treatment of breast cancerHormonal treatment of breast cancer
Hormonal treatment of breast cancerSantam Chakraborty
 
Role and Side effects of Ovarian Function Suppression in Breast Cancer
Role  and Side effects of Ovarian Function Suppression in Breast CancerRole  and Side effects of Ovarian Function Suppression in Breast Cancer
Role and Side effects of Ovarian Function Suppression in Breast CancerAjeet Gandhi
 
Treatment of her2 positive breast cancer
Treatment of her2 positive breast cancerTreatment of her2 positive breast cancer
Treatment of her2 positive breast cancerManar Malik
 
PARP inhibitor in Ca Ovary
PARP inhibitor in Ca OvaryPARP inhibitor in Ca Ovary
PARP inhibitor in Ca OvaryChandan K Das
 
Treatment paradigms in tnbc
Treatment paradigms in tnbcTreatment paradigms in tnbc
Treatment paradigms in tnbcmadurai
 
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCEREVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCERIsha Jaiswal
 
Changing landscape in the treatment of advanced prostate cancer
Changing landscape in the treatment of advanced prostate cancer Changing landscape in the treatment of advanced prostate cancer
Changing landscape in the treatment of advanced prostate cancer Alok Gupta
 
Hormone therapy for carcinoma breast
Hormone therapy for carcinoma breastHormone therapy for carcinoma breast
Hormone therapy for carcinoma breastParag Roy
 
Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer Chandan K Das
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast CancerMohamed Abdulla
 
Advances in management of hormone sensitive prostate cancer
Advances in management of hormone sensitive prostate cancerAdvances in management of hormone sensitive prostate cancer
Advances in management of hormone sensitive prostate cancerAlok Gupta
 
Management of the premenopausal er+ve breast cancer
Management of the premenopausal er+ve breast cancerManagement of the premenopausal er+ve breast cancer
Management of the premenopausal er+ve breast cancerAhmed Allam
 
trials on Chemotherapy in breast cancer
trials on Chemotherapy in breast cancer trials on Chemotherapy in breast cancer
trials on Chemotherapy in breast cancer Dr.Rashmi Yadav
 
Bladder preservation for CA Urinary Bladder
Bladder preservation for CA Urinary BladderBladder preservation for CA Urinary Bladder
Bladder preservation for CA Urinary BladderAnil Gupta
 
Endocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast CancerEndocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast Cancerguest8887a7
 
Aurelia asco 20121
Aurelia asco 20121Aurelia asco 20121
Aurelia asco 20121lefein
 
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
The Changing Role of PARP Inhibitors in the Treatment of Ovarian CancerThe Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancerbkling
 

La actualidad más candente (20)

Hormonal treatment of breast cancer
Hormonal treatment of breast cancerHormonal treatment of breast cancer
Hormonal treatment of breast cancer
 
Role and Side effects of Ovarian Function Suppression in Breast Cancer
Role  and Side effects of Ovarian Function Suppression in Breast CancerRole  and Side effects of Ovarian Function Suppression in Breast Cancer
Role and Side effects of Ovarian Function Suppression in Breast Cancer
 
Treatment of her2 positive breast cancer
Treatment of her2 positive breast cancerTreatment of her2 positive breast cancer
Treatment of her2 positive breast cancer
 
PARP inhibitor in Ca Ovary
PARP inhibitor in Ca OvaryPARP inhibitor in Ca Ovary
PARP inhibitor in Ca Ovary
 
Treatment paradigms in tnbc
Treatment paradigms in tnbcTreatment paradigms in tnbc
Treatment paradigms in tnbc
 
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCEREVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
EVOLUTION OF CHEMOTHERAPY IN BREAST CANCER
 
Portec trial ppt
Portec trial pptPortec trial ppt
Portec trial ppt
 
Changing landscape in the treatment of advanced prostate cancer
Changing landscape in the treatment of advanced prostate cancer Changing landscape in the treatment of advanced prostate cancer
Changing landscape in the treatment of advanced prostate cancer
 
Hormone therapy for carcinoma breast
Hormone therapy for carcinoma breastHormone therapy for carcinoma breast
Hormone therapy for carcinoma breast
 
Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast Cancer
 
Advances in management of hormone sensitive prostate cancer
Advances in management of hormone sensitive prostate cancerAdvances in management of hormone sensitive prostate cancer
Advances in management of hormone sensitive prostate cancer
 
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptxLANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
LANDMARK CHEMOTHERAPY TRIALS in Carcinoma Ovary.pptx
 
Management of the premenopausal er+ve breast cancer
Management of the premenopausal er+ve breast cancerManagement of the premenopausal er+ve breast cancer
Management of the premenopausal er+ve breast cancer
 
trials on Chemotherapy in breast cancer
trials on Chemotherapy in breast cancer trials on Chemotherapy in breast cancer
trials on Chemotherapy in breast cancer
 
Bladder preservation for CA Urinary Bladder
Bladder preservation for CA Urinary BladderBladder preservation for CA Urinary Bladder
Bladder preservation for CA Urinary Bladder
 
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptxMANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
MANAGEMENT OF TRIPLE NEGATIVE BREAST CANCER.pptx
 
Endocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast CancerEndocrine Therapy In Advanced Breast Cancer
Endocrine Therapy In Advanced Breast Cancer
 
Aurelia asco 20121
Aurelia asco 20121Aurelia asco 20121
Aurelia asco 20121
 
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
The Changing Role of PARP Inhibitors in the Treatment of Ovarian CancerThe Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
 

Destacado

Tumor Dormancy
Tumor DormancyTumor Dormancy
Tumor Dormancybkling
 
New Developments in Breast Reconstruction Surgery
New Developments in Breast Reconstruction SurgeryNew Developments in Breast Reconstruction Surgery
New Developments in Breast Reconstruction Surgerybkling
 
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...bkling
 
Immunotherapy Update for Ovarian Cancer
Immunotherapy Update for Ovarian Cancer Immunotherapy Update for Ovarian Cancer
Immunotherapy Update for Ovarian Cancer bkling
 
Facing Forward: When Cancer Changes the Road Ahead
Facing Forward: When Cancer Changes the Road AheadFacing Forward: When Cancer Changes the Road Ahead
Facing Forward: When Cancer Changes the Road Aheadbkling
 
Metastatic Breast Cancer Awareness Day: Special Event Webinar
Metastatic Breast Cancer Awareness Day: Special Event WebinarMetastatic Breast Cancer Awareness Day: Special Event Webinar
Metastatic Breast Cancer Awareness Day: Special Event Webinarbkling
 
SHARE: Metastatic Breast Cancer: Cutting-Edge Research from National Cancer w...
SHARE: Metastatic Breast Cancer: Cutting-Edge Research from National Cancer w...SHARE: Metastatic Breast Cancer: Cutting-Edge Research from National Cancer w...
SHARE: Metastatic Breast Cancer: Cutting-Edge Research from National Cancer w...bkling
 
Report Back from ASCO on Metastatic Breast Cancer
Report Back from ASCO on Metastatic Breast CancerReport Back from ASCO on Metastatic Breast Cancer
Report Back from ASCO on Metastatic Breast Cancerbkling
 
Clinical Trials for Metastatic Breast Cancer
Clinical Trials for Metastatic Breast CancerClinical Trials for Metastatic Breast Cancer
Clinical Trials for Metastatic Breast Cancerbkling
 
DCIS: What You Need to Know
DCIS: What You Need to KnowDCIS: What You Need to Know
DCIS: What You Need to Knowbkling
 
Ovarian Cancer: What's New?
Ovarian Cancer: What's New?Ovarian Cancer: What's New?
Ovarian Cancer: What's New?bkling
 
Strategies for Long-term Management of Recurrent Ovarian Cancer
Strategies for Long-term Management of Recurrent Ovarian CancerStrategies for Long-term Management of Recurrent Ovarian Cancer
Strategies for Long-term Management of Recurrent Ovarian Cancerbkling
 
Patient Perspective on Strategies for Long-Term Management of Recurrent Ovari...
Patient Perspective on Strategies for Long-Term Management of Recurrent Ovari...Patient Perspective on Strategies for Long-Term Management of Recurrent Ovari...
Patient Perspective on Strategies for Long-Term Management of Recurrent Ovari...bkling
 
The family center disability webinar for share sept 2017
The family center   disability webinar for share sept 2017The family center   disability webinar for share sept 2017
The family center disability webinar for share sept 2017bkling
 
Your Sexuality After Cancer
Your Sexuality After CancerYour Sexuality After Cancer
Your Sexuality After Cancerbkling
 
Difficult Conversations: Bridging the Communication Gap with your Oncologist
Difficult Conversations: Bridging the Communication Gap with your OncologistDifficult Conversations: Bridging the Communication Gap with your Oncologist
Difficult Conversations: Bridging the Communication Gap with your Oncologistbkling
 
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium bkling
 
SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...
SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...
SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...bkling
 
Finding a Clinical Trial That's Right for You
Finding a Clinical Trial That's Right for YouFinding a Clinical Trial That's Right for You
Finding a Clinical Trial That's Right for Youbkling
 
Immunotherapy for Metastatic Triple Negative Breast Cancer
Immunotherapy for Metastatic Triple Negative Breast CancerImmunotherapy for Metastatic Triple Negative Breast Cancer
Immunotherapy for Metastatic Triple Negative Breast Cancerbkling
 

Destacado (20)

Tumor Dormancy
Tumor DormancyTumor Dormancy
Tumor Dormancy
 
New Developments in Breast Reconstruction Surgery
New Developments in Breast Reconstruction SurgeryNew Developments in Breast Reconstruction Surgery
New Developments in Breast Reconstruction Surgery
 
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
 
Immunotherapy Update for Ovarian Cancer
Immunotherapy Update for Ovarian Cancer Immunotherapy Update for Ovarian Cancer
Immunotherapy Update for Ovarian Cancer
 
Facing Forward: When Cancer Changes the Road Ahead
Facing Forward: When Cancer Changes the Road AheadFacing Forward: When Cancer Changes the Road Ahead
Facing Forward: When Cancer Changes the Road Ahead
 
Metastatic Breast Cancer Awareness Day: Special Event Webinar
Metastatic Breast Cancer Awareness Day: Special Event WebinarMetastatic Breast Cancer Awareness Day: Special Event Webinar
Metastatic Breast Cancer Awareness Day: Special Event Webinar
 
SHARE: Metastatic Breast Cancer: Cutting-Edge Research from National Cancer w...
SHARE: Metastatic Breast Cancer: Cutting-Edge Research from National Cancer w...SHARE: Metastatic Breast Cancer: Cutting-Edge Research from National Cancer w...
SHARE: Metastatic Breast Cancer: Cutting-Edge Research from National Cancer w...
 
Report Back from ASCO on Metastatic Breast Cancer
Report Back from ASCO on Metastatic Breast CancerReport Back from ASCO on Metastatic Breast Cancer
Report Back from ASCO on Metastatic Breast Cancer
 
Clinical Trials for Metastatic Breast Cancer
Clinical Trials for Metastatic Breast CancerClinical Trials for Metastatic Breast Cancer
Clinical Trials for Metastatic Breast Cancer
 
DCIS: What You Need to Know
DCIS: What You Need to KnowDCIS: What You Need to Know
DCIS: What You Need to Know
 
Ovarian Cancer: What's New?
Ovarian Cancer: What's New?Ovarian Cancer: What's New?
Ovarian Cancer: What's New?
 
Strategies for Long-term Management of Recurrent Ovarian Cancer
Strategies for Long-term Management of Recurrent Ovarian CancerStrategies for Long-term Management of Recurrent Ovarian Cancer
Strategies for Long-term Management of Recurrent Ovarian Cancer
 
Patient Perspective on Strategies for Long-Term Management of Recurrent Ovari...
Patient Perspective on Strategies for Long-Term Management of Recurrent Ovari...Patient Perspective on Strategies for Long-Term Management of Recurrent Ovari...
Patient Perspective on Strategies for Long-Term Management of Recurrent Ovari...
 
The family center disability webinar for share sept 2017
The family center   disability webinar for share sept 2017The family center   disability webinar for share sept 2017
The family center disability webinar for share sept 2017
 
Your Sexuality After Cancer
Your Sexuality After CancerYour Sexuality After Cancer
Your Sexuality After Cancer
 
Difficult Conversations: Bridging the Communication Gap with your Oncologist
Difficult Conversations: Bridging the Communication Gap with your OncologistDifficult Conversations: Bridging the Communication Gap with your Oncologist
Difficult Conversations: Bridging the Communication Gap with your Oncologist
 
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium
Invasive Lobular Carcinoma — Highlights from the First Ever ILC Symposium
 
SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...
SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...
SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...
 
Finding a Clinical Trial That's Right for You
Finding a Clinical Trial That's Right for YouFinding a Clinical Trial That's Right for You
Finding a Clinical Trial That's Right for You
 
Immunotherapy for Metastatic Triple Negative Breast Cancer
Immunotherapy for Metastatic Triple Negative Breast CancerImmunotherapy for Metastatic Triple Negative Breast Cancer
Immunotherapy for Metastatic Triple Negative Breast Cancer
 

Similar a SHARE Webinar: Latest Research on Metastatic Breast Cancer from SABCS 2015

PARPi in CA Breast 1.pptx
PARPi in CA Breast 1.pptxPARPi in CA Breast 1.pptx
PARPi in CA Breast 1.pptxShrutiBehl2
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancerspa718
 
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Pharma Intelligence
 
Updates On Upper Gastrointestinal Malignancies 2015
Updates On Upper Gastrointestinal Malignancies 2015Updates On Upper Gastrointestinal Malignancies 2015
Updates On Upper Gastrointestinal Malignancies 2015OSUCCC - James
 
What’s the Latest in Clear Cell Ovarian Cancer?
What’s the Latest in Clear Cell Ovarian Cancer?What’s the Latest in Clear Cell Ovarian Cancer?
What’s the Latest in Clear Cell Ovarian Cancer?bkling
 
What’s New with PARP Inhibitors and Ovarian Cancer?
What’s New with PARP Inhibitors and Ovarian Cancer?What’s New with PARP Inhibitors and Ovarian Cancer?
What’s New with PARP Inhibitors and Ovarian Cancer?bkling
 
Role of olaparib in breast and ovarian cancers
Role of olaparib in breast and ovarian cancersRole of olaparib in breast and ovarian cancers
Role of olaparib in breast and ovarian cancersSabeena Choudhary
 
Palbociclib in Metastatic Breast Cancer
Palbociclib in Metastatic Breast CancerPalbociclib in Metastatic Breast Cancer
Palbociclib in Metastatic Breast CancerVibhay Pareek
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancerMohamed Abdulla
 
Treatment paradigms in the management of mbc bgicc 2014
Treatment paradigms in the management of mbc bgicc 2014 Treatment paradigms in the management of mbc bgicc 2014
Treatment paradigms in the management of mbc bgicc 2014 Mohamed Abdulla
 
The Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast CancerThe Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast CancerDana-Farber Cancer Institute
 
Immunotherapy in uro oncolgy
Immunotherapy in uro oncolgyImmunotherapy in uro oncolgy
Immunotherapy in uro oncolgyAlok Gupta
 
New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Drive...
New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Drive...New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Drive...
New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Drive...i3 Health
 
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLCJournal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLCAnimesh Agrawal
 
What's New in Treatment and Clinical Trials for Advanced Triple-Negative Brea...
What's New in Treatment and Clinical Trials for Advanced Triple-Negative Brea...What's New in Treatment and Clinical Trials for Advanced Triple-Negative Brea...
What's New in Treatment and Clinical Trials for Advanced Triple-Negative Brea...Dana-Farber Cancer Institute
 
04_Joaquim_Bellmunt.ppsx
04_Joaquim_Bellmunt.ppsx04_Joaquim_Bellmunt.ppsx
04_Joaquim_Bellmunt.ppsxMariaGrunwald
 
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Fight Colorectal Cancer
 
GI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarGI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarFight Colorectal Cancer
 

Similar a SHARE Webinar: Latest Research on Metastatic Breast Cancer from SABCS 2015 (20)

PARPi in CA Breast 1.pptx
PARPi in CA Breast 1.pptxPARPi in CA Breast 1.pptx
PARPi in CA Breast 1.pptx
 
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast CancerUpdate on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancer
 
Update in tnbc
Update in tnbcUpdate in tnbc
Update in tnbc
 
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
 
Updates On Upper Gastrointestinal Malignancies 2015
Updates On Upper Gastrointestinal Malignancies 2015Updates On Upper Gastrointestinal Malignancies 2015
Updates On Upper Gastrointestinal Malignancies 2015
 
Targeting Advanced Triple-Negative Breast Cancer
Targeting Advanced Triple-Negative Breast CancerTargeting Advanced Triple-Negative Breast Cancer
Targeting Advanced Triple-Negative Breast Cancer
 
What’s the Latest in Clear Cell Ovarian Cancer?
What’s the Latest in Clear Cell Ovarian Cancer?What’s the Latest in Clear Cell Ovarian Cancer?
What’s the Latest in Clear Cell Ovarian Cancer?
 
What’s New with PARP Inhibitors and Ovarian Cancer?
What’s New with PARP Inhibitors and Ovarian Cancer?What’s New with PARP Inhibitors and Ovarian Cancer?
What’s New with PARP Inhibitors and Ovarian Cancer?
 
Role of olaparib in breast and ovarian cancers
Role of olaparib in breast and ovarian cancersRole of olaparib in breast and ovarian cancers
Role of olaparib in breast and ovarian cancers
 
Palbociclib in Metastatic Breast Cancer
Palbociclib in Metastatic Breast CancerPalbociclib in Metastatic Breast Cancer
Palbociclib in Metastatic Breast Cancer
 
Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancer
 
Treatment paradigms in the management of mbc bgicc 2014
Treatment paradigms in the management of mbc bgicc 2014 Treatment paradigms in the management of mbc bgicc 2014
Treatment paradigms in the management of mbc bgicc 2014
 
The Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast CancerThe Latest Treatments for HER2-Positive Breast Cancer
The Latest Treatments for HER2-Positive Breast Cancer
 
Immunotherapy in uro oncolgy
Immunotherapy in uro oncolgyImmunotherapy in uro oncolgy
Immunotherapy in uro oncolgy
 
New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Drive...
New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Drive...New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Drive...
New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Drive...
 
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLCJournal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLC
 
What's New in Treatment and Clinical Trials for Advanced Triple-Negative Brea...
What's New in Treatment and Clinical Trials for Advanced Triple-Negative Brea...What's New in Treatment and Clinical Trials for Advanced Triple-Negative Brea...
What's New in Treatment and Clinical Trials for Advanced Triple-Negative Brea...
 
04_Joaquim_Bellmunt.ppsx
04_Joaquim_Bellmunt.ppsx04_Joaquim_Bellmunt.ppsx
04_Joaquim_Bellmunt.ppsx
 
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...
 
GI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 WebinarGI ASCO 2019 Updates – January 2019 Webinar
GI ASCO 2019 Updates – January 2019 Webinar
 

Más de bkling

Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...
Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...
Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...bkling
 
Let's Talk About It: Uterine Cancer (Advance Care Planning)
Let's Talk About It: Uterine Cancer (Advance Care Planning)Let's Talk About It: Uterine Cancer (Advance Care Planning)
Let's Talk About It: Uterine Cancer (Advance Care Planning)bkling
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
 
Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)
Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)
Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)bkling
 
Let's Talk About It: Sick and Tired of Being Sick and Tired
Let's Talk About It: Sick and Tired of Being Sick and TiredLet's Talk About It: Sick and Tired of Being Sick and Tired
Let's Talk About It: Sick and Tired of Being Sick and Tiredbkling
 
Caring for You: The Mental & Emotional Toll of Survivorship
Caring for You: The Mental & Emotional Toll of SurvivorshipCaring for You: The Mental & Emotional Toll of Survivorship
Caring for You: The Mental & Emotional Toll of Survivorshipbkling
 
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...bkling
 
Ways to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side EffectsWays to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side Effectsbkling
 
Part II: DCIS Research: De-escalating the Fear of Recurrence
Part II: DCIS Research: De-escalating the Fear of RecurrencePart II: DCIS Research: De-escalating the Fear of Recurrence
Part II: DCIS Research: De-escalating the Fear of Recurrencebkling
 
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...bkling
 
Sharing Our Own Experience- A Qualitative Study with Black Women Diagnosed wi...
Sharing Our Own Experience- A Qualitative Study with Black Women Diagnosed wi...Sharing Our Own Experience- A Qualitative Study with Black Women Diagnosed wi...
Sharing Our Own Experience- A Qualitative Study with Black Women Diagnosed wi...bkling
 
Part I: Not all DCIS is "Risky"
Part I: Not all DCIS is "Risky"Part I: Not all DCIS is "Risky"
Part I: Not all DCIS is "Risky"bkling
 
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)bkling
 
Let's Talk About It: Ovarian Cancer (Dealing with Cancer Treatment Burnout)
Let's Talk About It: Ovarian Cancer (Dealing with Cancer Treatment Burnout)Let's Talk About It: Ovarian Cancer (Dealing with Cancer Treatment Burnout)
Let's Talk About It: Ovarian Cancer (Dealing with Cancer Treatment Burnout)bkling
 
Let’s Talk About It: Ovarian Cancer (Self-Compassion: The Gift You Give Yours...
Let’s Talk About It: Ovarian Cancer (Self-Compassion: The Gift You Give Yours...Let’s Talk About It: Ovarian Cancer (Self-Compassion: The Gift You Give Yours...
Let’s Talk About It: Ovarian Cancer (Self-Compassion: The Gift You Give Yours...bkling
 
Understanding Uterine Cancer Treatment Options
Understanding Uterine Cancer Treatment OptionsUnderstanding Uterine Cancer Treatment Options
Understanding Uterine Cancer Treatment Optionsbkling
 
Let's Talk About It: Breast Cancer (The History and Advances in Radiation The...
Let's Talk About It: Breast Cancer (The History and Advances in Radiation The...Let's Talk About It: Breast Cancer (The History and Advances in Radiation The...
Let's Talk About It: Breast Cancer (The History and Advances in Radiation The...bkling
 
Scalp Cooling 101
Scalp Cooling 101Scalp Cooling 101
Scalp Cooling 101bkling
 
The Cost of Cancer: Financial Burdens of Treatment
The Cost of Cancer: Financial Burdens of TreatmentThe Cost of Cancer: Financial Burdens of Treatment
The Cost of Cancer: Financial Burdens of Treatmentbkling
 
Let's Talk About It: Ovarian Cancer (Working with the Darker Feelings of Canc...
Let's Talk About It: Ovarian Cancer (Working with the Darker Feelings of Canc...Let's Talk About It: Ovarian Cancer (Working with the Darker Feelings of Canc...
Let's Talk About It: Ovarian Cancer (Working with the Darker Feelings of Canc...bkling
 

Más de bkling (20)

Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...
Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...
Vaccines: Will they become a form of Secondary and Primary Breast Cancer Prev...
 
Let's Talk About It: Uterine Cancer (Advance Care Planning)
Let's Talk About It: Uterine Cancer (Advance Care Planning)Let's Talk About It: Uterine Cancer (Advance Care Planning)
Let's Talk About It: Uterine Cancer (Advance Care Planning)
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
 
Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)
Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)
Understanding and Managing Chemo-Induced Peripheral Neuropathy (CIPN)
 
Let's Talk About It: Sick and Tired of Being Sick and Tired
Let's Talk About It: Sick and Tired of Being Sick and TiredLet's Talk About It: Sick and Tired of Being Sick and Tired
Let's Talk About It: Sick and Tired of Being Sick and Tired
 
Caring for You: The Mental & Emotional Toll of Survivorship
Caring for You: The Mental & Emotional Toll of SurvivorshipCaring for You: The Mental & Emotional Toll of Survivorship
Caring for You: The Mental & Emotional Toll of Survivorship
 
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
Let's Talk About It: Ovarian Cancer (Shifting Focus: The Relationship with Yo...
 
Ways to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side EffectsWays to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side Effects
 
Part II: DCIS Research: De-escalating the Fear of Recurrence
Part II: DCIS Research: De-escalating the Fear of RecurrencePart II: DCIS Research: De-escalating the Fear of Recurrence
Part II: DCIS Research: De-escalating the Fear of Recurrence
 
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
Report Back from San Antonio Breast Cancer Symposium (SABCS) 2023: Spotlight ...
 
Sharing Our Own Experience- A Qualitative Study with Black Women Diagnosed wi...
Sharing Our Own Experience- A Qualitative Study with Black Women Diagnosed wi...Sharing Our Own Experience- A Qualitative Study with Black Women Diagnosed wi...
Sharing Our Own Experience- A Qualitative Study with Black Women Diagnosed wi...
 
Part I: Not all DCIS is "Risky"
Part I: Not all DCIS is "Risky"Part I: Not all DCIS is "Risky"
Part I: Not all DCIS is "Risky"
 
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
Report Back from 2023 San Antonio Breast Cancer Symposium (SABCS)
 
Let's Talk About It: Ovarian Cancer (Dealing with Cancer Treatment Burnout)
Let's Talk About It: Ovarian Cancer (Dealing with Cancer Treatment Burnout)Let's Talk About It: Ovarian Cancer (Dealing with Cancer Treatment Burnout)
Let's Talk About It: Ovarian Cancer (Dealing with Cancer Treatment Burnout)
 
Let’s Talk About It: Ovarian Cancer (Self-Compassion: The Gift You Give Yours...
Let’s Talk About It: Ovarian Cancer (Self-Compassion: The Gift You Give Yours...Let’s Talk About It: Ovarian Cancer (Self-Compassion: The Gift You Give Yours...
Let’s Talk About It: Ovarian Cancer (Self-Compassion: The Gift You Give Yours...
 
Understanding Uterine Cancer Treatment Options
Understanding Uterine Cancer Treatment OptionsUnderstanding Uterine Cancer Treatment Options
Understanding Uterine Cancer Treatment Options
 
Let's Talk About It: Breast Cancer (The History and Advances in Radiation The...
Let's Talk About It: Breast Cancer (The History and Advances in Radiation The...Let's Talk About It: Breast Cancer (The History and Advances in Radiation The...
Let's Talk About It: Breast Cancer (The History and Advances in Radiation The...
 
Scalp Cooling 101
Scalp Cooling 101Scalp Cooling 101
Scalp Cooling 101
 
The Cost of Cancer: Financial Burdens of Treatment
The Cost of Cancer: Financial Burdens of TreatmentThe Cost of Cancer: Financial Burdens of Treatment
The Cost of Cancer: Financial Burdens of Treatment
 
Let's Talk About It: Ovarian Cancer (Working with the Darker Feelings of Canc...
Let's Talk About It: Ovarian Cancer (Working with the Darker Feelings of Canc...Let's Talk About It: Ovarian Cancer (Working with the Darker Feelings of Canc...
Let's Talk About It: Ovarian Cancer (Working with the Darker Feelings of Canc...
 

Último

World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 

Último (20)

World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 

SHARE Webinar: Latest Research on Metastatic Breast Cancer from SABCS 2015

  • 1. Latest Research on Metastatic Breast Cancer from San Antonio Breast Cancer Symposium 2015 and beyond Tiffany A.Traina, MD Section Head,Triple Negative Breast Cancer Clinical Research Program Associate Member, Breast Medicine Service, Department of Medicine Memorial Sloan Kettering Cancer Center Assistant Professor of Medicine, Weill Cornell Medicine
  • 2. Topics of interest from SABCS 2015 • Neoadjuvant carboplatin • IMMU-132 TNBC • TH3RESA trialHER2+ • JAVELIN • KEYNOTE Immunotherapy • ABCSG18 • CREATE-X Other
  • 4. Why platinums inTNBC? • Platinum activity in BRCA- associated BC – BRCA1 is a key mediator of DNA damage response – BRCA deficient cells have impaired ability to repair damage • 80% of BRCA1-associated BC areTN • “BRCAness” ofTNBC – SporadicTNBC have genomic instability similar to BRCA1-associated breast cancer • High pCR rates inTNBC pilot trials Wilson C A , et al Nat Genet 1999;21:236
  • 5. GeparSixto: Does carboplatin increase response? von Minckwitz et al Lancet Oncology 2014 Jun; 15(7) N = 315
  • 6. Yes, Carboplatin increases pCR pCR (ypT0N0) von Minckwitz et al Lancet Oncology 2014 Jun; 15(7)
  • 7. CALGB 40603: Does carboplatin increase pCR? Sikov et al, J Clin Oncol 2015 Jan 1;33(1):13-21 Paclitaxel 80 mg/m2 wkly x 12 ddAC x 4 Bevacizumab 10 mg/kg q2wks x 9 Bevacizumab 10 mg/kg q2wks x 9 CarboplatinAUC 6 q3wks x 4 CarboplatinAUC 6 q3wks x 4 Paclitaxel 80mg/m2 weekly x 12 Surgery XRT No Adjuvant Systemic Treatment Planned Paclitaxel 80 mg/m2 wkly x 12 Paclitaxel 80 mg/m2 wkly x 12 Paclitaxel 80 mg/m2 wkly x 12 ddAC x 4 ddAC x 4 ddAC x 4 N = 443 2 X 2 Randomization Primary Endpoint: pCR Breast (ypT0/is N any) Key Eligibility St II-III ER/PR <10% HER2 (-)
  • 8. N=212 Yes, Carboplatin increases pCR 46% (40-53%) 60% (54-66%) Odds Ratio: 1.76 p = 0.0018 41% (35-48%) 54% (48-61%) Odds ratio: 1.71 p = 0.0029
  • 9. PaclitaxelddAC Significant side effects limit tolerability Slide courtesy of Bill Sikov; SABCS 2013
  • 10. Von Minckwitz et al S2-04 SABCS 2015 Geparsixto: DFS improved with addition of carboplatin 3 yr DFS: 76.1% vs. 85.8% HR 0.59 P=0.03
  • 11. Sikov et al S2-05 SABCS 2015 CALGB: Carboplatin did NOT improve breast cancer related survival
  • 12. CALGB: Carboplatin did NOT improve OS using a conventional anthracycline, cyclophosphamide and taxane containing regimen Sikov et al S2-05 SABCS 2015
  • 13. Why the discrepancy? Challenge of pCR as a surrogate endpoint Berry D and HudisC, JAMAOncology, July 2015 • Trials were not powered to show survival advantage • Statistically, need a very large pCR difference to see a survival advantage Many unanswered questions re: the role of platinum inTNBC • Does the backbone regimen matter? • Does type of platinum matter?
  • 14. For individual trials, no association between pCR and survival benefit Cortazar et al, Lancet July 2014
  • 15. Is neoadjuvant platinum a new standard? No, data fell short and uncertainty remains • Await molecular/biomarker correlatives to narrowly select who may benefit – BRCA status – Other markers of DNA repair problems (HRD) • Carboplatin added to anthracycline/taxane reasonable when the goal of pre-op therapy is to reduce tumor volume • Would not routinely recommend platinum in the adjuvant setting forTNBC based on these data
  • 17. Sacituzumab Govitecan (IMMU-132) A next-generation irinotecan of interest inTNBC • Trop-2 expressed in >90% ofTNBC • IMMU-132 is a antibody-drug conjugate of humanized anti-Trop- 2 coupled with SN-38, the active metabolite of irinotecan • Phase I/II ongoing – N = 60 patients withTNBC – ≥2 prior chemotherapy regimens; median of 5 priors – ORR = 31% (18/58);CBR24 = 45% – Median PFS 6 months (95% CI: 4.1- 9.4mo) – Most common side effects: low white cells, diarrhea, fatigue, anemia – Serious diarrhea 3% (relatively rare) Bardia et al, Abstract #1016; ASCO 2015; SABCS 2015
  • 18. FDA Assigns Sacituzumab Govitecan Breakthrough Designation forTNBC! February 8, 2016 "We believe breakthrough therapy designation for IMMU- 132 further validates this potential therapeutic for patients withTNBC, and we are delighted to receive this important recognition." Cynthia L. Sullivan President and CEO of Immunomedics “The planned phase III trial of sacituzumab govitecan, on which Immunomedics is working with the FDA, is a multicenter, international, randomized, open-label study that aims to accrue 328 patients with relapsed/refractory metastaticTNBC following ≥2 prior chemotherapies, including a taxane.The primary outcome measure will be PFS, with secondary endpoints includingOS,ORR, duration of response, and time to onset of response.”
  • 20. Hudis C. N Engl J Med 2007;357:39-51; Slamon et al NEJM 2001; Targeting HER2 improves breast cancer survival!
  • 21. T-DM1 Average number DM1 molecules/monoclonal antibody=3.5 1. Beeram M., et al. J Clin Oncol. 2008; 26 (May 20 suppl; abstr 1028).
  • 22. TDM1 vs.TPC in HER2+ MBC Wildiers et al; SABCS 2015
  • 23. TDM1 improves OS in HER2+ MBC Wildiers et al; SABCS 2015
  • 25. Immunotherapy rationale • Normal part of immune regulation • Antibodies that block the PD-1 pathway can reactivate T-cell activity and proliferation • Leading to enhanced antitumour immunity Wolchok & Chan Nature 2014 Pembrolizumab Nivolumab Atezolizumab
  • 26. Immunotherapy forTNBC TNBCs have high PD-L1 Early but encouraging results Pembrolizumab (SABCS 2014) • PD1 inhibitor. Blocks ability of tumor to deactivate immune system • Small Phase 1 trial • Responses in ~20% of women with PD-L1+TNBC • Well tolerated Atezolizumab = MPDL3280A (AACR 2015) • PD-1 inhibitor • Small Phase 1 trial • Responses in ~20% of patients • Well tolerated
  • 27. Many potential immunotherapy trials! Pembrolizumab 1. Pembrolizumab + capecitabine or paclitaxel (PI Heather McArthur) 2. Pembrolizumab + eribulin (industry) 3. Carboplatin +/- pembro (TBCRC: PI Hope Rugo) 4. Pembro vs.TPC (Industry) Atezolizumab (MPDL3280A ) • Carboplatin +/- atezolizumab (TBCRC: Vanderbilt) • Nab-paclitaxel +/- atezolizumab (Industry)
  • 28. JAVELIN: Ph 1b of Avelumab in SolidTumors Trial Design • Fully humanized anti-PD1 antibody • Expansion cohort MBC – </= 3 lines of cytotoxic tx – PriorT + A – Unselected for PD-L1 expression or molecular subtype Patient Characteristics • TNBC 35% • ER+ 43% • HER2+ 15% • Median 3 regimens (0-10) Dirix et al; SABCS 2015
  • 30. Activity of avelumab in pts with MBC Dirix et al; SABCS 2015
  • 31. KEYNOTE: Pembrolizumab in PD-L1+ ER+ MBC Pembrolizumab • Anti-PD-L1 antibody • Activity in PD-L1+TNBC – ORR 19% (5/27; Nanda SABCS 2014) – 3/5 responders on drug >11m • PD-L1 expression inversely correlated with ER expression KEYNOTE-028 • Phase 1b multicohort trial – ER+ HER2- MBC – Failure of or inability to receive standard therapy – PD-L1+ (≥1% tumor or stroma) – Measurable disease • Pembrolizumab 10mg/kg q2 weeks until 8 week scan – Confirmed POD after 4 weeks – CR/PR/SD to 24mo or POD or tox Rugo et al; SABCS 2015
  • 32. KEYNOTE-028 Pt Characteristics • 19% (48) of 261 screened were PD-L1+ • N=25 on study – 44% had ≥5 prior lines Rugo et al; SABCS 2015
  • 33. ABCSG-18: A role for “adjuvant” denosumab
  • 34. ABCSG18: Background • Adjuvant bisphosphonates have been associated with a significantly reduced rate of breast cancer recurrence in bone and improved survival in postmenopausal women with breast cancer[1] • ABCSG18 trial: phase III trial of denosumab vs placebo in AI-treated postmenopausal women with early HR+ breast cancer – Primary analysis: significant reduction in fracture risk with denosumab vs placebo[2] • HR: 0.50 (95% CI: 0.39-0.65; P < .0001) – IDMC recommended unblinding following results of primary analysis, with DFS analysis to be completed before unblinding • SABCS report from the ABCSG18 study includes the impact of denosumab on DFS in postmenopausal pts with early HR+ breast cancer on AIs[3] 1. EBCTCG, et al. Lancet. 2015;386:1353-1361. 2. Gnant M, et al. Lancet. 2015;386:433-443. 3. Gnant M, et al. SABCS 2015. Abstract S2-02.
  • 35. ABCSG-18: Study Design • Prospective, randomized, double-blind, placebo-controlled phase III trial • Primary endpoint: time to first clinical fracture • Secondary endpoints: % change in BMD, vertebral fractures, DFS, OS, BoneM+FS, safety Postmenopausal pts with early HR+ breast cancer receiving adjuvant AI therapy* (N = 3425) Denosumab 60 mg SC Q6M (n = 1711) Placebo SC Q6M (n = 1709) Gnant M, et al. Lancet. 2015;386:433-443. *Pts excluded if history of IV bisphosphonate, SERMS,Cushing’s disease, Paget’s disease, hypercalcemia, hypocalcemia, hyperprolactinemia, or other active metabolic bone disease.
  • 36. ABCSG-18: Disease-Free Survival • ITT analysis consistent with sensitivity analysis in which pts switching to another bone-active treatment were censored – Hazard ratio, denosumab vs placebo: 0.807 (95% CI: 0.66-0.99; P = .0424) Gnant M, et al. SABCS 2015. Abstract S2-02. Impact of Denosumab vs Placebo on DFS (ITT) 100 90 80 70 60 0 Disease-FreeSurvival(%) Mos Since Randomization 900 6 12 18 24 30 36 42 48 54 60 66 72 78 84 93.8% 88.9% 83.5% 92.6% 86.8% 80.4% .0510Placebo Denosumab Number of Events/Patients HR (95% CI) vs Placebo P value 203/1709 167/1711 0.816 (0.66-1.00)
  • 37. Denosumab improves DFS when consider cross-over Gnant et al; SABCS 2015
  • 38. Indirect Comparison with EBCTCG, Lancet 2015
  • 39. Denosumab data is consistent with EBCTG
  • 40. 3% absolute reduction in breast cancer mortality in post-menopausal women (18%)
  • 41. CREATE-X: Ph III trial of adjuvant capecitabine
  • 42. Does capecitabine improve DFS after pre-op chemo? Lee S-J,Toi et al; SABCS 2015 Capecitabine 2,500 mg/m2/day po Day 1-14 in a 21-day cycle x6 cycles ** Safety interim analysis after N=50, IDMC recommended 8 cycles of tx
  • 43. CREATE-XTrial Design Statistics • Primary endpoint 5y DFS – Estimate 62% vs 70% – HR 0.74, 2 sided alpha 5% – 352 events expected from 900 pts – Planned 1 interim analysis for DFS at 2 years Eligibility • Age 20-74 • Stage I-IIIB • HER2 negative • Non-pCR and/or LN+ after pre-operative chemotherapy • No prior oral 5-FU Lee S-J,Toi et al; SABCS 2015
  • 44. CREATE-X Results Patient characteristics • Med age 48y • ~60% Premenopausal • ~40% Stage III • ~60% LN+ • ~63% ER+ • NeoadjTx Received – A+T/AT 94% – TC 1% – 5-FU containing 60% • Endocrine tx (67%) and radiation (72%) Capecitabine Compliance • Reduced: 24-37% • Discontinued: ~18-25% ≥Gr 3Tox Control Capecitabine Neutropenia 1.6% 6.6% Diarrhea 0.4% 3% HFS 10.9% Lee S-J,Toi et al; SABCS 2015
  • 45. Capecitabine improves DFS/OS following pre- operative chemotherapy Lee S-J,Toi et al; SABCS 2015 5% improvement in overall survival! Across all subsets 42% improvement ifTNBC
  • 47. Cutting edge technology to personalize cancer treatment!
  • 48. Clinical trial enrolling now at MSK… Device Drugs Lead PI:Traina. NCT# 02521363